NCT01321879View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions

InfectionBacteremia

Interventions

DRUG

Telavancin

10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston